A patient starts a new prescription for gout, seizures, pain relief, or an infection. At first, everything seems normal.
A few days later, they develop a fever. Then come body aches, a sore throat, and what feels like the flu. Many people assume they picked up a virus or caught a seasonal illness.
What they don’t realize is that their immune system may be launching a devastating reaction to starting a new drug.
For people diagnosed with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), when the illness actually began matters because the timing of symptoms often helps doctors determine whether a new treatment is responsible for the reaction.
Medications Commonly Linked to SJS and When Symptoms Appear
Medical researchers have consistently found that Stevens-Johnson syndrome most often develops shortly after a new drug is started. The highest-risk period falls within the first one to eight weeks after beginning treatment, with symptoms commonly appearing between four and 28 days. Some researchers estimate that it takes approximately four weeks of continuous use of a drug for many cases of SJS/TEN to develop.
Although Stevens-Johnson syndrome is rare and affects only about one to three people per million people each year in the U.S., medications are believed to cause up to 80% of adult cases. As a result, physicians evaluating a possible SJS diagnosis typically review everything a patient has taken during the previous several weeks.
A wide range of prescription and over-the-counter medications has been associated with Stevens-Johnson syndrome. Those most commonly linked to SJS include anticonvulsants and antiseizures; allopurinol, used to treat gout; certain antibiotics, including sulfonamide antibiotics; nonsteroidal anti-inflammatory drugs (NSAIDs); and some cancer therapies and immunomodulating drugs.
Not every medicine follows the same timeline and can vary depending on the patient's individual immune response. Certain anticonvulsants, in particular, may trigger Stevens-Johnson syndrome several weeks after treatment begins. In some cases, symptoms don't appear until six to eight weeks. Researchers have also identified especially high relative risks among some anticonvulsants and newer cancer therapies, making careful monitoring during the first two months of treatment particularly important.
At the other end of the spectrum, some may trigger symptoms much more quickly. Published case reports have documented Stevens-Johnson syndrome and toxic epidermal necrolysis developing within only a few days after taking commonly used over-the-counter medicines, including acetaminophen. Patients who have previously experienced SJS/TEN from a specific medication may face an even faster reaction if they are exposed to it again. In some cases, symptoms can develop within hours of re-exposure.
One fact that surprises many survivors is that SJS doesn’t always begin while a patient is actively taking the medication. Symptoms can sometimes appear up to two weeks after the culprit drug has already been discontinued.
A patient may finish a course of antibiotics or stop another product and believe they are no longer at risk, only to develop fever, flu-like symptoms, or a rash days later. This delayed reaction can complicate diagnosis and may initially cause healthcare providers to overlook the source of the problem.
The Early SJS Warning Signs Often Look Like the Flu
One reason Stevens-Johnson syndrome is frequently misdiagnosed is that its earliest symptoms rarely resemble a skin disorder. Instead, patients often experience what appears to be a common illness. Fever, sore throat, cough, fatigue, body aches, and burning or irritated eyes may develop several days before the more recognizable and serious skin symptoms appear.
As the condition progresses, painful red or purple rashes can emerge. Many patients develop the characteristic target-like lesions associated with SJS. Blisters may form on the skin and mucous membranes, including the eyes, mouth, and genitals. The affected skin may become extremely painful, and the outer layer of skin can begin to separate from the body, creating injuries similar to severe burns.
Stevens-Johnson syndrome exists on a disease spectrum with toxic epidermal necrolysis (TEN), a more extensive and life-threatening form of the same condition. Doctors generally classify a reaction as SJS when less than 10% of the body's surface area is affected. When skin detachment involves more than 30% of the body, the condition is classified as TEN. Cases falling between those ranges are often referred to as SJS/TEN overlap syndrome.
As skin loss spreads, patients face a growing risk of dehydration, infection, sepsis, respiratory complications, organ damage, and permanent injuries affecting the eyes, skin, and other organs. Many patients require treatment in intensive care units or specialized burn centers, where medical teams focus on stopping the progression of the reaction, managing pain, preventing infection, replacing fluids, and protecting damaged tissues.
TEN carries a significantly higher risk of death than Stevens-Johnson syndrome alone. Some studies have reported mortality rates approaching 25% to 30% in severe cases. Survivors may face lasting complications, including chronic eye disease, vision loss, scarring, skin sensitivity, breathing problems, and significant emotional trauma.
Because the disease can progress rapidly from flu-like symptoms to a medical emergency, recognizing the early warning signs of SJS and seeking immediate medical attention can be lifesaving. The sooner the suspected medicine is identified and discontinued, the better the chances of limiting the damage caused by the reaction.
When Delayed Diagnosis Leads to Catastrophic Harm
Timing not only helps identify what’s causing SJS. It can also reveal whether opportunities for earlier diagnosis were missed.
Many patients seek medical treatment during the flu-like phase of the illness. Unfortunately, healthcare providers may initially diagnose a viral infection, upper respiratory illness, conjunctivitis, or a minor drug reaction. If the underlying Stevens-Johnson syndrome is not recognized, patients may continue taking the medicine that is triggering the reaction. Those lost days can have devastating consequences.
Prompt identification of SJS often leads physicians to discontinue the suspected drug and begin intensive supportive treatment immediately. Delays may allow the disease to progress to widespread blistering, skin loss, infection, organ complications, permanent eye damage, or death.
Understanding the Legal Questions After an SJS Diagnosis
For many survivors, the physical recovery from SJS or TEN is only part of the story. Medical bills can be overwhelming. Some patients require treatment in specialized burn centers or intensive care units. Others face permanent vision problems, chronic pain, scarring, mental health challenges, and the inability to return to work.
In some situations, serious legal questions arise. Pharmaceutical manufacturers have a duty to adequately warn patients and healthcare providers about known or reasonably foreseeable risks associated with their products. When evidence suggests a company failed to provide sufficient warnings about the risk of Stevens-Johnson syndrome, injured patients may have grounds to pursue a pharmaceutical liability claim.
Medical providers may also be held responsible in Stevens-Johnson syndrome medical malpractice lawsuits when warning signs are missed or when a patient presenting with classic symptoms is repeatedly misdiagnosed despite recent exposure to a high-risk medication.
Every case is different, but survivors may be entitled to seek compensation for medical expenses, lost income, pain and suffering, emotional distress, permanent disabilities, and other damages related to the injury.
If you or a loved one developed SJS or TEN after taking a prescription or over-the-counter drug, it may be important to speak with an attorney experienced in handling Stevens-Johnson syndrome cases. A qualified lawyer can review the timing of the medication, the warnings provided, the medical treatment received, and whether legal options may be available.
